Are we ready for top-down therapy for inflammatory bowel diseases: pro

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Conventional treatments for inflammatory bowel diseases (IBD) include mesalazine, corticosteroids, and thiopurines, with variable efficacy.
• Despite advancements, many IBD patients experience disabling disease courses and reduced quality of life.
• The advent of biologics targeting specific inflammatory pathways has shifted treatment paradigms.

Purpose of the Study:

• To evaluate the readiness for a 'top-down' treatment approach utilizing biologics in IBD management.
• To discuss the optimal timing for introducing biologic therapies in ulcerative colitis and Crohn's disease.

Main Methods:

• Review of current literature on IBD treatment strategies.
• Analysis of factors influencing treatment decisions, including quality of life, corticosteroid dependence, and surgical necessity.
• Exploration of the 'top-down' versus 'bottom-up' therapeutic approaches.

Main Results:

• Biologics targeting TNF and other pathways represent significant advancements in IBD therapy.
• The discussion centers on early versus late introduction of biologics.
• Quality of life, corticosteroid use, and surgery rates are key considerations.

Conclusions:

• The optimal timing for initiating biologic therapy in IBD remains a critical question.
• A 'top-down' approach with early biologic use may offer benefits but requires careful consideration of patient-specific factors.
• Further research is needed to establish definitive guidelines for early biologic intervention in ulcerative colitis and Crohn's disease.